The non-exclusive agreement provides Biogenuix with the rights to distribute in India.
Among the standardized RT-PCR (StaRT-PCR) based research molecular tools are kits for chronic myelogenous leukemia, lung cancer risk prediction and inflammation/rheumatoid arthritis. The reagents include a selection of more than 600 StaRT-PCR internal standards.
Jonathan Rowe, COO of Gene Express, said: “This will be the first time that Gene Express’s patented standardized gene expression technology will be made widely available to Indian researchers. By partnering with a valuable partner in Biogenuix, we are confident that the Gene Express tests and reagents will be widely accepted in the Indian research market.”